Formulation optimization of prostaglandin E₁-loaded lipid emulsion: Enhanced stability and reduced biodegradation

References

• Hoshi K. Approved indications of lipo-PGE1 in Japan. Adv Drug Deliver Rev 1996;20:171–176.
   Google Scholar
• Milio G, Cospite V, Cospite M. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease. Minerva Cardioangiol 2003;51:311–316.
   PubMedGoogle Scholar
• Della Rocca G, Coccia C, Pompei L, Costa MG, Di Marco P, Pietropaoli P. Inhaled aerosolized prostaglandin E1, pulmonary hemodynamics, and oxygenation during lung transplantation. Minerva Anestesiol 2008;74:627–633.
   PubMed Web of Science ®Google Scholar
• Milcan A, Arslan E, Bagdatoglu OT, Bagdatoglu C, Polat G, Kanik A et al. The effect of alprostadil on ischemia-reperfusion injury of peripheral nerve in rats. Pharmacol Res 2004;49:67–72.
   PubMed Web of Science ®Google Scholar
• Stehle RG, Oesterling TO. Stability of prostaglandin E1 and dinoprostone (prostaglandin E2) under strongly acidic and basic conditions. J Pharm Sci 1977;66:1590–1595.
   PubMedGoogle Scholar
• Gu FG, Cui FD, Gao YL. Preparation of prostaglandin E1-hydroxypropyl-beta-cyclodextrin complex and its nasal delivery in rats. Int J Pharm 2005;290:101–108.
   PubMed Web of Science ®Google Scholar
• Sood BG, Peterson J, Malian M, Galli R, Geisor-Walter M, McKinnon J et al. Jet nebulization of prostaglandin E1 during neonatal mechanical ventilation: stability, emitted dose and aerosol particle size. Pharmacol Res 2007;56:531–541.
   PubMedGoogle Scholar
• Eierman DF, Yagami M, Erme SM, Minchey SR, Harmon PA, Pratt KJ et al. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci USA 1995;92:2815–2819.
   PubMed Web of Science ®Google Scholar
• Feld S, Li G, Amirian J, Felli P, Vaughn WK, Accad M et al. Enhanced thrombolysis, reduced coronary reocclusion and limitation of infarct size with liposomal prostaglandin E1 in a canine thrombolysis model. J Am Coll Cardiol 1994;24:1382–1390.
   PubMedGoogle Scholar
• Gao Y, Xu P, Chen L, Li Y. Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect. Int J Pharm 2010;387:263–271.
   PubMed Web of Science ®Google Scholar
• Ishihara T, Takahashi M, Higaki M, Takenaga M, Mizushima T, Mizushima Y. Prolonging the in vivo residence time of prostaglandin E(1) with biodegradable nanoparticles. Pharm Res 2008;25:1686–1695.
   PubMed Web of Science ®Google Scholar
• Pan H, Kopecková P, Liu J, Wang D, Miller SC, Kopecek J. Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates. Pharm Res 2007;24:2270–2280.
   PubMed Web of Science ®Google Scholar
• Momma K. Lipo-PGE1 treatment of the neonate with critical congenital heart disease and ductus-arteriosus dependent circulation. Adv Drug Deliver Rev 1996;20:177–180.
   Google Scholar
• Teagarden DL, Anderson BD, Petre WJ. Dehydration kinetics of prostaglandin E1 in a lipid emulsion. Pharm Res 1989;6:210–215.
   PubMed Web of Science ®Google Scholar
• Gatti R, Gotti R, Cavrini V, Soli M, Bertaccini A, Carparelli F. Stability study of prostaglandin E1 (PGE1) in physiological solutions by liquid chromatography (HPLC). Int J Pharm1995;115:113–117.
   Google Scholar
• Monkhouse DC, Van Campen L, Aguiar AJ. Kinetics of dehydration and isomerization of prostaglandins E 1 and E 2. J Pharm Sci 1973;62:576–580.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang Y, Tang X. Formulation and thermal sterile stability of a less painful intravenous clarithromycin emulsion containing vitamin E. Int J Pharm 2008;346:47–56.
   PubMed Web of Science ®Google Scholar
• Grit M, de Smidt JH, Struijke A, Crommelin Daan JA. Hydrolysis of phosphatidylcholine in aqueous liposome dispersions. Int J Pharm 1989;50:1–6.
   Web of Science ®Google Scholar
• Grit M, Zuidam NJ, Underberg WJ, Crommelin DJ. Hydrolysis of partially saturated egg phosphatidylcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics. J Pharm Pharmacol 1993;45:490–495.
   PubMed Web of Science ®Google Scholar
• Yu YL, Lu Y, Tang X, Cui FD. Formulation, preparation and evaluation of an intravenous emulsion containing Brucea javanica oil and Coix Seed oil for anti-tumor application. Biol Pharm Bull 2008;31:673–680.
   PubMed Web of Science ®Google Scholar
• Jumaa M, Müller BW. The stabilization of parenteral fat emulsion using non-ionic ABA copolymer surfactant. Int J Pharm 1998;174:29–37.
   Web of Science ®Google Scholar
• Herman CJ, Groves MJ. Hydrolysis kinetics of phospholipids in thermally stressed intravenous lipid emulsion formulations. J Pharm Pharmacol 1992;44:539–542.
   PubMed Web of Science ®Google Scholar
• Herman CJ, Groves MJ. The influence of free fatty acid formation on the pH of phospholipid-stabilized triglyceride emulsions. Pharm Res 1993;10:774–776.
   PubMedGoogle Scholar
• Shi S, Chen H, Cui Y, Tang X. Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion. Int J Pharm 2009;373:147–155.
   PubMed Web of Science ®Google Scholar
• Wulff-Pérez M, Torcello-Gómez A, Gálvez-Ruíz MJ, Martín-Rodríguez A. Stability of emulsions for parenteral feeding: Preparation and characterization of o/w nanoemulsions with natural oils and Pluronic F-68 as surfactant. Food Hydrocolloids. 2009;23:1096–102.
   Web of Science ®Google Scholar
• Available at: http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm.
   Google Scholar
• Dickinson E. Hydrocolloids at interfaces and the influence on the properties of dispersed systems. Food Hydrocolloids. 2003;17:25–39.
   Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. Pharmaceutical Press. London 2006; 535–538.
   Google Scholar
• Weingarten C, Santos Magalhaes NS, Baszkin A, Benoita S, Seiller M. Interaction of a non-ionic ABA copolymer surfactant with phospholipid monolayers: Possible relevance to emulsion stabilization. Int J Pharm 1991;75:171–179.
   Google Scholar
• Jumaa M, Müller BW. The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int J Pharm 1998;163:81–89.
   Web of Science ®Google Scholar
• Levy MY, Benita S, Baszkin A. Interactions of a non-ionic surfactant with mixed phospholipid–oleic acid monolayers. Studies under dynamic conditions. Colloids Surf 1991;59:225–241.
   Google Scholar
• Washington C, Davis SS. Ageing effects in patenterai fat emulsions: the role of fatty acids. Int J Pharm 1987;39:33–37.
   Web of Science ®Google Scholar
• Lu Y, Zhang Y, Yang Z, Tang X. Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm 2009;366:160–169.
   PubMed Web of Science ®Google Scholar
• Teagarden DL, Anderson BD, Petre WJ. Determination of the pH-dependent phase distribution of prostaglandin E1 in a lipid emulsion by ultrafiltration. Pharm Res 1988;5:482–487.
   PubMedGoogle Scholar
• Stehle RG. Physical chemistry, stability, and handling of prostaglandins E2, F2α, D2, and I2: A critical summary. Methods Enzymol 1982;86:436–458.
   Web of Science ®Google Scholar
• Yamaguchi T, Fukushima Y, Itai S, Hayashi H. Rate of release and retentivity of prostaglandin E1 in lipid emulsion. Biochim Biophys Acta 1995;1256:381–386.
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Vane JR. Prostaglandins: their disappearance from and release into the circulation. Nature 1967;216:868–873.
   PubMed Web of Science ®Google Scholar
• Hansen HS. 15-hydroxyprostaglandin dehydrogenase. A review. Prostaglandins 1976;12:647–679.
   PubMedGoogle Scholar
• Nakano J, Prancan AV, Morsy NH. Metabolism of prostaglandin E1 in stomach, jejunum chyle and plasma of the dog and the rat. Jpn J Pharmacol 1973;23:355–361.
   PubMedGoogle Scholar
• Tamaguchi T. Lipid microspheres as drug carriers: a pharmaceutical point of view. Int J Pharm 1996;20:117–130.
   Google Scholar
• Fairn GD, McMaster CR. Studying phospholipid metabolism using yeast systematic and chemical genetics. Methods 2005;36:102–108.
   PubMedGoogle Scholar
• Manevich Y, Fisher AB. Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med 2005;38:1422–1432.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Lee MH, Shim CK. Inverse targeting of drugs to reticuloendothelial system-rich organs by lipid microemulsion emulsified with poloxamer 338. Int J Pharm 1995; 113:175–187.
   Web of Science ®Google Scholar